** Healthcare company Grifols GRLS.MC sinks to the bottom of IBEX 35 index, shares falling about 6% after 2025 full-year results, as it fails to deliver a promising outlook for revenue growth in 2026
** The company did not provide specific revenue guidance as it will now focus on margins, cash flow and deleveraging, but added it expects moderate growth at constant exchange rates for 2026
** J.P. Morgan says a downgrade to 2026 EBITDA and the slowdown in underlying revenue growth are reasons for the shares falling
** The broker sees slower revenue growth as Grifols is moving from volume-driven growth to margin-driven growth
** The company's shares are on track for its worst day since April 2025
(Reporting by Gemma Guasch)
((Gemma.guasch@thomsonreuters.com ;))
Comments